- Home
- JSPR vs RCEL Comparison
JSPR vs RCEL Comparison
Compare JSPR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- RCEL
- Stock Information
- Founded
- JSPR 2018
- RCEL 2020
- Country
- JSPR United States
- RCEL United States
- Employees
- JSPR N/A
- RCEL N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- RCEL Medical/Dental Instruments
- Sector
- JSPR Health Care
- RCEL Health Care
- Exchange
- JSPR Nasdaq
- RCEL Nasdaq
- Market Cap
- JSPR 321.8M
- RCEL 342.7M
- IPO Year
- JSPR N/A
- RCEL N/A
- Fundamental
- Price
- JSPR $21.03
- RCEL $11.56
- Analyst Decision
- JSPR Strong Buy
- RCEL Hold
- Analyst Count
- JSPR 11
- RCEL 3
- Target Price
- JSPR $73.38
- RCEL $16.50
- AVG Volume (30 Days)
- JSPR 174.0K
- RCEL 95.3K
- Earning Date
- JSPR 11-07-2024
- RCEL 11-07-2024
- Dividend Yield
- JSPR N/A
- RCEL N/A
- EPS Growth
- JSPR N/A
- RCEL N/A
- EPS
- JSPR N/A
- RCEL N/A
- Revenue
- JSPR N/A
- RCEL $60,040,000.00
- Revenue This Year
- JSPR N/A
- RCEL $40.34
- Revenue Next Year
- JSPR N/A
- RCEL $52.79
- P/E Ratio
- JSPR N/A
- RCEL N/A
- Revenue Growth
- JSPR N/A
- RCEL 32.24
- 52 Week Low
- JSPR $5.00
- RCEL $7.51
- 52 Week High
- JSPR $31.01
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- JSPR 45.81
- RCEL 40.54
- Support Level
- JSPR $19.41
- RCEL $12.06
- Resistance Level
- JSPR $23.11
- RCEL $12.75
- Average True Range (ATR)
- JSPR 1.83
- RCEL 0.69
- MACD
- JSPR -0.21
- RCEL -0.21
- Stochastic Oscillator
- JSPR 24.40
- RCEL 5.77
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.